Saturday, April 19, 2014
Inquirer Daily News

FDA Advisers Revisit Heart Risks Posed by Painkillers

NEW YORK - DECEMBER 21: A bottle of the over-the-counter pain reliever Aleve is seen December 21, 2004 in New York City. It has been reported that elderly patients taking naproxen, the drug´s generic name, were found to have a 50% greater chance of suffering strokes or heart attacks than those taking a placebo. (Photo Illustration by Mario Tama/Getty Images)
NEW YORK - DECEMBER 21: A bottle of the over-the-counter pain reliever Aleve is seen December 21, 2004 in New York City. It has been reported that elderly patients taking naproxen, the drug's generic name, were found to have a 50% greater chance of suffering strokes or heart attacks than those taking a placebo. (Photo Illustration by Mario Tama/Getty Images)

MONDAY, Feb. 10, 2014 (HealthDay News) -- Naproxen -- the key pain reliever in Aleve -- seems safer for the heart than other popular anti-inflammatory drugs such as ibuprofen (Advil and Motrin), U.S. health officials say.

And it's possible that labeling will soon reflect that finding.

Advisers to the U.S. Food and Drug Administration are meeting Monday and Tuesday to discuss cardiac risks associated with non-steroidal anti-inflammatory drugs, sometimes called NSAIDs.

Millions of people take these medicines, which also include the prescription drug Celebrex, to relieve muscle aches, headaches and pain from arthritis and injuries.

More coverage
  • Using 3-D printing to treat children's heart defects
  • Since 2005, labeling laws have required a heart warning on these anti-inflammatory drugs. That stemmed from Merck's withdrawal of the NSAID Vioxx from the market in 2004 because of a notable increased risk of heart attack among Vioxx users.

    But naproxen doesn't seem to carry the same risks as the other NSAIDs, an FDA panel recently concluded after a safety review involving 350,000 people using different pain relievers. The panel posted its findings online last week.

    If the FDA does approve a labeling change, that could make Aleve and other naproxen-containing drugs the preferred drug for patients who have a risk of heart problems, Ira Loss, a pharmaceutical analyst with Washington Analysis, told the Associated Press. However, all NSAIDs will still need to warn of risks for internal bleeding and ulceration, Loss said.

    The FDA isn't required to follow its advisory panel's recommendations, but it frequently does.

    Aspirin, another type of NSAID, isn't a focus of this week's hearings.

    "The question of whether naproxen, the key ingredient in Aleve and other generic pain pills, has a lower risk of heart attack and stroke than medications, such as Advil, that contain ibuprofen, is an interesting debate," said Victoria Richards, an assistant professor of medical sciences at the Frank H. Netter MD School of Medicine at Quinnipiac University in Connecticut.

    "All NSAIDS (non-steroidal anti-inflammatory drugs) come with black box warnings indicating cardiovascular and gastrointestinal risks," Richards added in a news release. "Although both ibuprofen and naproxen belong to the same class of NSAIDS, research suggests that naproxen has a significantly lower risk of cardiovascular events than ibuprofen, although the dose of ibuprofen may be taken into consideration. This lower risk might be seen with low-dose ibuprofen."

    More information

    The American College of Rheumatology has more about pain relievers.

     

    -- HealthDay staff

    SOURCES: Feb. 10, 2014, news release, U.S. Food and Drug Administration; Victoria Richards, Ph.D., assistant professor of medical sciences, the Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, Conn.; Associated Press

    Copyright © 2014 HealthDay. All rights reserved.
    Latest Health Videos
    Also on Philly.com:
    Stay Connected